Journal
CURRENT RHEUMATOLOGY REPORTS
Volume 14, Issue 1, Pages 99-106Publisher
SPRINGER
DOI: 10.1007/s11926-011-0223-5
Keywords
Antiphospholipid syndrome; Stroke; Ischemic stroke; Lupus anticoagulant; Anticardiolipin; Management; Thrombosis
Categories
Funding
- National Institutes of Health/National Heart, Lung, and Blood Institute [1R01 HL096944]
Ask authors/readers for more resources
Ischemic stroke is one of the most common complications of the antiphospholipid syndrome (APS). Because of the relative lack of definitive prospective studies, there is still some debate as to whether the persistent presence of antiphospholipid antibodies (aPLs) increases the risk of recurrent stroke. There is more evidence for aPLs as a risk factor for first stroke. The mechanisms of ischemic stroke are considered to be thrombotic and embolic. APS patients with thrombotic stroke frequently have other, often conventional vascular risk factors. Transesophageal echocardiogram is strongly recommended in APS patients with ischemic stroke because of the high yield of valvular abnormalities. The appropriate management of thrombosis in patients with APS is still controversial because of limited randomized clinical trial data. This review discusses the current evidence for antithrombotic therapy in patients who are aPL positive but do not fulfill criteria for APS, and in APS patients. Alternative and emerging therapies including low molecular weight heparin, new oral anticoagulants (including direct thrombin inhibitors), hydroxychloroquine, statins, and rituximab, are also addressed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available